

Anti-ICOS/CD278 Antibody (Alomfilimab)

Introduction

KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody directed against the inducible co-stimulatory receptor (ICOS). KY-1044 depletes cells with high ICOS via antibody-dependent cellular cytotoxicity (ADCC) with the engagement of FcγR11a. KY-1044 acts as a co-stimulatory molecule on cells expressing lower ICOS levels, such as CD8⁺ T Eff cells (via FcγR-dependent aggregation). KY-1044 exploits the differential expression of ICOS on T cell subtypes to improve the intratumoral immune environment and restore anti-tumor immune responses.

Product parameters

Alternative Names	KY 1044, SAR445256
Target Accession	Q9Y6W8
Target	ICOS / CD278
CAS number	2378692-24-9
Molecular Weight	146.5 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The purity of Anti-ICOS/CD278 Antibody (Alomfilimab) is more than 95%, determined by SEC-HPLC.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μm filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

